Regulatory T cells-an important target for cancer immunotherapy.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

5 citing papers in PubMed.

1. LADS: a powerful vaccine platform for cancer immunotherapy and prevention.BMC biology · 2024
   Article
2. A New Trend in Cancer Treatment: The Combination of Epigenetics and Immunotherapy.Frontiers in immunology · 2022
   Review
3. The emerging role of epigenetic therapeutics in immuno-oncology.Nature reviews. Clinical oncology · 2020
   Review
4. Delineation of an immunosuppressive gradient in hepatocellular carcinoma using high-dimensional proteomic and transcriptomic analyses.Proceedings of the National Academy of Sciences of the United States of America · 2017
   Article
5. Reply: Regulatory T cells-an important target for cancer immunotherapy.Nature reviews. Clinical oncology · 2014
   Article

Corrections and comments

• Commented on by
  Reply: Regulatory T cells-an important target for cancer immunotherapy.2014
• Comment on
  Breathing new life into immunotherapy: review of melanoma, lung and kidney cancer.2014

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as